MX2015012318A - Formas de estado solido de un derivado de quinazolina y su uso como un inhibidor de braf. - Google Patents

Formas de estado solido de un derivado de quinazolina y su uso como un inhibidor de braf.

Info

Publication number
MX2015012318A
MX2015012318A MX2015012318A MX2015012318A MX2015012318A MX 2015012318 A MX2015012318 A MX 2015012318A MX 2015012318 A MX2015012318 A MX 2015012318A MX 2015012318 A MX2015012318 A MX 2015012318A MX 2015012318 A MX2015012318 A MX 2015012318A
Authority
MX
Mexico
Prior art keywords
solid state
state forms
quinazoline derivative
braf inhibitor
application
Prior art date
Application number
MX2015012318A
Other languages
English (en)
Inventor
Martin J Jacobs
Stephen J Bierlmaier
Ralph C Haltiwanger
Original Assignee
Ignyta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ignyta Inc filed Critical Ignyta Inc
Publication of MX2015012318A publication Critical patent/MX2015012318A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Esta solicitud se refiere a varias sales y formas de estado sólido del Compuesto (I) La solicitud también se refiere a composiciones farmacéuticas y usos farmacéuticos de estos materiales y composiciones.
MX2015012318A 2013-03-11 2014-03-11 Formas de estado solido de un derivado de quinazolina y su uso como un inhibidor de braf. MX2015012318A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361776081P 2013-03-11 2013-03-11
PCT/US2014/023110 WO2014164648A2 (en) 2013-03-11 2014-03-11 Solid state forms of a quinazoline derivative and its use as a braf inhibitor

Publications (1)

Publication Number Publication Date
MX2015012318A true MX2015012318A (es) 2016-04-15

Family

ID=50771322

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012318A MX2015012318A (es) 2013-03-11 2014-03-11 Formas de estado solido de un derivado de quinazolina y su uso como un inhibidor de braf.

Country Status (15)

Country Link
US (3) US9353097B2 (es)
EP (1) EP2956454A2 (es)
JP (1) JP2016512516A (es)
KR (1) KR20150132118A (es)
CN (1) CN105051039A (es)
AU (2) AU2014249158B2 (es)
BR (1) BR112015022207A8 (es)
CA (1) CA2901204C (es)
EA (1) EA025561B1 (es)
HK (2) HK1217193A1 (es)
IL (1) IL241239A0 (es)
MX (1) MX2015012318A (es)
NZ (1) NZ710600A (es)
TW (1) TW201512192A (es)
WO (1) WO2014164648A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015012318A (es) 2013-03-11 2016-04-15 Ignyta Inc Formas de estado solido de un derivado de quinazolina y su uso como un inhibidor de braf.
US10799503B2 (en) 2016-12-01 2020-10-13 Ignyta, Inc. Methods for the treatment of cancer
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN111153860B (zh) * 2019-12-30 2021-06-29 广州六顺生物科技股份有限公司 一种喹唑啉类化合物的晶型及其制备方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070244120A1 (en) * 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
PT2268623E (pt) * 2008-03-17 2015-09-17 Ambit Biosciences Corp Derivados de quinazolina como moduladores de cinase raf e métodos para utilização dos mesmos
EP2694677A2 (en) * 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
MX2015012318A (es) 2013-03-11 2016-04-15 Ignyta Inc Formas de estado solido de un derivado de quinazolina y su uso como un inhibidor de braf.

Also Published As

Publication number Publication date
CN105051039A (zh) 2015-11-11
US9987281B2 (en) 2018-06-05
IL241239A0 (en) 2015-11-30
CA2901204C (en) 2018-07-10
TW201512192A (zh) 2015-04-01
AU2014249158B2 (en) 2016-07-28
BR112015022207A2 (pt) 2017-07-18
KR20150132118A (ko) 2015-11-25
US20150376171A1 (en) 2015-12-31
AU2014249158A1 (en) 2015-09-17
AU2016204294A1 (en) 2016-07-14
US20160280698A1 (en) 2016-09-29
US9718810B2 (en) 2017-08-01
CA2901204A1 (en) 2014-10-09
US20170290833A1 (en) 2017-10-12
EP2956454A2 (en) 2015-12-23
WO2014164648A4 (en) 2015-01-29
NZ710600A (en) 2017-01-27
EA025561B1 (ru) 2017-01-30
US9353097B2 (en) 2016-05-31
WO2014164648A2 (en) 2014-10-09
EA201591259A1 (ru) 2016-02-29
HK1217193A1 (zh) 2016-12-30
JP2016512516A (ja) 2016-04-28
WO2014164648A3 (en) 2014-11-27
HK1217333A1 (zh) 2017-01-06
AU2016204294B9 (en) 2017-09-21
AU2016204294B2 (en) 2017-08-31
BR112015022207A8 (pt) 2018-01-23

Similar Documents

Publication Publication Date Title
PH12016500467A1 (en) Aminoheteroarlyl benzamides as kinase inhibitors
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
PH12015501996B1 (en) Heterocyclic compounds and uses thereof
NZ716840A (en) Combination formulation of two antiviral compounds
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
AU2016204294A1 (en) Solid State Forms Of A Quinazoline Derivative And Its Use As A BRAF Inhibitor
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
UA108101C2 (xx) Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
PH12015501843A1 (en) Novel pyrazol derivatives
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
UA116239C2 (uk) Нові похідні піридину
UA115357C2 (uk) Похідні піридин-4-ілу
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
BR112014030720A8 (pt) composto, composição farmacêutica e usos de inibidores de fbx03
EA201500821A1 (ru) Производные 2-замещенных-6-биарилметиламино-9-циклопентил-9н-пуринов, их использование в качестве лекарственных средств и фармацевтических составов
EA201270728A1 (ru) Пуриновые соединения
MX366651B (es) Forma a cristalina de (r)-2-((3-(3-aminopiperidin-1-il)-6-metil-5- oxo-1,2,4-triazin-4(5h)-il)metil)-4-fluorobenzonitrilo monobenzoato y método de preparación del mismo y composición farmacéutica que comprende la misma.
MX2015016766A (es) Nuevos derivados de tetrazolona.
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.